Page last updated: 2024-11-04

phenylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID999
CHEMBL ID1044
CHEBI ID30745
SCHEMBL ID1459
MeSH IDM0084151

Synonyms (104)

Synonym
benzenacetic acid
nsc-125718
.omega.-phenylacetic acid
acetic acid, phenyl-
phenylethanoic acid
nsc125718
.alpha.-toluic acid
alpha-toluic acid
omega-phenylacetic acid
CHEBI:30745 ,
NCI60_002571
einecs 203-148-6
fema no. 2878
nsc 125718
kyselina fenyloctova [czech]
ai3-08920
benzylcarboxylic acid
hsdb 5010
brn 1099647
phenylacetic acid (natural)
phenyllacetic acid
2-phenylacetic acid
inchi=1/c8h8o2/c9-8(10)6-7-4-2-1-3-5-7/h1-5h,6h2,(h,9,10
phenyl-acetic acid
STK297835
103-82-2
benzylformic acid
phenylacetic acid
benzeneacetic acid
C07086
phenylacetic acid, 99%
phenylacetic acid, plant cell culture tested
phenylacetic acid, >=99%, fcc, fg
phenylacetic acid, natural, >=99%
NCGC00159477-02
nsc139637
nsc-139637
51146-16-8
NCI60_000596
bdbm16419
phenylacetate, xix
chembl1044 ,
8727557E-AA75-49E9-8E5A-7A2412D71888
AKOS000291351
benzeneacetiic acid
BMSE000220
NCGC00159477-03
phenyl acetic acid
unii-er5i1w795a
4-09-00-01614 (beilstein handbook reference)
kyselina fenyloctova
ec 203-148-6
er5i1w795a ,
dtxsid2021656 ,
NCGC00258087-01
dtxcid201656
tox21_200533
tox21_113042
cas-103-82-2
2-phenyl-acetic acid
FT-0641197
organic white solid
PHENYLACETIC ACID_GURUDEEBANSATYAVANI
BP-11383
EPITOPE ID:116202
1173020-54-6
phenylacetic acid [hsdb]
tropicamide impurity d [ep impurity]
procaine benzylpenicillin impurity e [ep impurity]
antineoplaston as 2-1 component phenylacetic acid
astugenal component phenylacetic acid
benzylpenicillin potassium impurity b [ep impurity]
phenylacetic acid [mi]
benzylpenicillin (benzathine) tetrahydrate impurity b { ep impurity]
phenylacetic acid [fhfi]
benzylpenicillin sodium impurity b [ep impurity]
antineoplaston as2-1 component phenylacetic acid
phenylacetic acid [fcc]
SCHEMBL1459
tox21_113042_1
NCGC00159477-05
phenylactic acid
DL-0063
DB09269
mfcd00004313
phenylacetic acid, analytical standard
phenylacetic acid, natural, >=99%, fg
tropicamide impurity d (phenylacetic acid - drug precursor), european pharmacopoeia (ep) reference standard
phenylessigsaure
a-toluate
omega-phenylacetate
phenylethanoate
a-toluic acid
w-phenylacetate
w-phenylacetic acid
alpha-toluate
FT-0701063
Q410842
phenylacetic
17303-65-0
tropicamide impurity d (ep impurity)
benzylpenicillin potassium impurity b (ep impurity)
benzylpenicillin sodium impurity b (ep impurity)
procaine benzylpenicillin impurity e (ep impurity)

Research Excerpts

Overview

Phenylacetic acid (PAA) is a common intermediate in the catabolic pathways of several structurally related aromatic compounds. PAA inhibits nitric oxide synthase expression and plasma membrane calcium ATPase and may therefore also be involved in remodeling of arteries.

ExcerptReferenceRelevance
"Phenylacetic acid (PAA) is a common intermediate in the catabolic pathways of several structurally related aromatic compounds. "( Phenylacetyl coenzyme A is an effector molecule of the TetR family transcriptional repressor PaaR from Thermus thermophilus HB8.
Agari, Y; Kuramitsu, S; Sakamoto, K; Shinkai, A, 2011
)
1.81
"Phenylacetic acid (PAA) is a recently described uremic toxin that inhibits inducible nitric oxide synthase expression and plasma membrane calcium ATPase and may therefore also be involved in remodeling of arteries. "( Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy.
Haass, W; Henning, L; Jankowski, J; Jankowski, V; Scholze, A; Suvd-Erdene, S; Tepel, M; Wittstock, A; Zidek, W, 2007
)
3.23

Effects

Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. Its role in plant growth and development remains unclear.

ExcerptReferenceRelevance
"Phenylacetic acid (PAA) has also been recognized as a natural auxin for >40 years, but its role in plant growth and development remains unclear."( Distinct Characteristics of Indole-3-Acetic Acid and Phenylacetic Acid, Two Common Auxins in Plants.
Dai, X; Estelle, M; Hanada, K; Hayashi, K; Hishiyama, S; Kakimoto, T; Kamiya, Y; Kasahara, H; Kawaide, H; Kinoshita-Tsujimura, K; Mashiguchi, K; Natsume, M; Sakai, T; Sugawara, S; Takebayashi, Y; Takeda-Kamiya, N; Tanaka, K; Yu, H; Zhao, Y, 2015
)
1.39
"Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin."( Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin.
Chambert, S; Fouque, D; Mafra, D; Saldanha, JF; Soula, HA; Soulage, CO; Stockler-Pinto, MB; Yi, D, 2016
)
1.4
"Phenylacetic acid has been measured using gas chromatographic and gas chromatographic-mass spectrometric methods."( Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid.
McQuade, PS, 1984
)
1.22

Toxicity

Phenylacetic acid and phenylacetylglutamine (PAGN) pharmacokinetic data and adverse events from five clinical studies were included in the analysis. PhenylAcetic acid plasma exposure was not correlated with neurologic adverse events in the ornithinephenylacetate target patient population.

ExcerptReferenceRelevance
" Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.81
" Glycerol phenylbutyrate (GPB) is safe and effective in reducing ammonia levels in patients with UCD above 2 months of age."( Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021
)
0.62
" All patients reported at least 1 treatment emergent adverse event with gastroesophageal reflux disease, vomiting, hyperammonemia, diaper dermatitis (37."( Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021
)
0.62
" Phenylacetic acid (PAA) plasma exposure has been reported to correlate with neurologic adverse events in patients with cancer but not in patients with urea cycle disorders or hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
1.9
"This analysis summarized the pharmacokinetics and safety of ornithine phenylacetate to support the dosing strategy and to assist with the monitoring and management of neurologic adverse events in a global clinical development program."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.99
"Phenylacetic acid and phenylacetylglutamine (PAGN) pharmacokinetic data and adverse events from five clinical studies were included in the analysis."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
2.43
" No correlation was observed between PAA plasma exposure and neurologic adverse events in patients with stable cirrhosis or acute hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.99
" Phenylacetic acid plasma exposure was not correlated with neurologic adverse events in the ornithine phenylacetate target patient population."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
1.9

Pharmacokinetics

Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) were regularly assessed. Plasma ammonia level was the primary pharmacodynamic variable.

ExcerptReferenceRelevance
" Site-specific, stable isotope-labeled phenelzine analogs were synthesized and used in metabolic and pharmacokinetic studies in humans."( Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans.
Cooper, TB; Corcella, J; Jindal, SP; Lutz, T; Robinson, DS, 1985
)
0.27
"Retrospective pharmacokinetic analysis."( Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Burstein, AH; Figg, WD; Reed, E; Tompkins, AC; Venzon, D, 2001
)
0.31
"The results of this study are similar to previous pharmacokinetic evaluations using the Abbottbase PKS system but suggest that earlier analyses were suboptimal."( Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Burstein, AH; Figg, WD; Reed, E; Tompkins, AC; Venzon, D, 2001
)
0.31
" We performed a pharmacokinetic study, as part of a phase I trial, of PAA in children with refractory cancer."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
"The capacity-limited conversion of PAA to PAG has important implications for the dosing of PAA, and the pharmacokinetic model described here may be useful for individualizing the infusion rate of the drug in future clinical trials."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
" A pharmacokinetic study of sodium phenylacetate/sodium benzoate (NAPA/NABZ) was performed in two groups of normal healthy volunteers, following the dosing regimen used to treat hyperammonemia."( Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers.
Altincatal, A; MacArthur, RB; Tuchman, M, 2004
)
0.32
" Because of the slower elimination of PA, and the non-linear pharmacokinetic behavior displayed by both PA and BZ, only investigational protocol-specific doses should be used, and higher doses should be avoided unless blood level monitoring can be done promptly and frequently."( Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers.
Altincatal, A; MacArthur, RB; Tuchman, M, 2004
)
0.32
" The objective of the present population pharmacokinetic modeling and simulation was to evaluate dose selection for target patient populations with a low body weight, ethnicity, and hepatic impairment in a global clinical study."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
0.94
"A population pharmacokinetic model was developed based on plasma concentrations of L-ornithine, phenylacetic acid, and phenylacetylglutamine data from four clinical trials in healthy subjects and patients with stable cirrhosis or hospitalized adult patients with liver cirrhosis and hepatic encephalopathy."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
1.16
" Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) (primary metabolite of PAA) were regularly assessed; plasma ammonia level was the primary pharmacodynamic variable."( Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Bajaj, JS; Bukofzer, S; Devarakonda, KR; Jamil, K; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Ram Bhamidimarri, K; Safadi, R; Thabut, D; Wang, L, 2022
)
1

Compound-Compound Interactions

ExcerptReferenceRelevance
" The antitumour effects of interferon alpha (IFN alpha) in combination with AS2-1, the hydrolysis product of 3-phenylacetyl-amino-2,6-piperidinedione, were examined using several human tumour cell lines as a model."( Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activity in-vitro.
Samid, D; Shack, S; Yeh, TJ, 1991
)
0.28
" The goals of this study were to determine whether PA and PB (a) are cytotoxic to malignant B cells from patients with non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia and (b) exhibit additive or synergistic induction of apoptosis when administered to myeloma cell lines in combination with conventional drugs."( Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.
Kaufmann, SH; Stenson, M; Svingen, PA; Timm, M; Witzig, TE, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The influence of nutrients and digestive secretions on the intestinal absorption and bioavailability of the beta-adrenoceptor antagonist, metoprolol, was investigated in an isolated segment of jejunum using an intestinal perfusion technique."( Investigation of drug absorption from the gastrointestinal tract of man. IV. Influence of food and digestive secretions on metoprolol jejunal absorption.
Bernier, JJ; Bovet, M; Duval, M; Evard, D; Godbillon, J; Hirtz, J; Schoeller, JP; Vidon, N, 1985
)
0.27
" These compounds may serve as useful leads for the design of nonpeptide inhibitors of SH2 domains with improved bioavailability and metabolic stability compared to the natural ligands that contain phosphotyrosine."( NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain.
Fesik, SW; Hajduk, PJ; Zhou, MM, 1999
)
0.3
"The effects of repeated treatment cycles and different doses on intraindividual variation in oral bioavailability of chlorambucil and its first, active, and more toxic metabolite, phenylacetic acid mustard, were studied."( Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses.
Malminiemi, K; Malminiemi, O; Seppälä, E; Silvennoinen, R; Vilpo, J, 2000
)
0.5
" bioavailability determination."( A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Baker, SD; Bowling, MK; Carducci, MA; Donehower, RC; Figg, WD; Gilbert, J; Grochow, L; Zabelina, Y, 2001
)
0.31
" Quinoline 16 showed good oral bioavailability and in vivo efficacy in a LDLr knockout mouse model for lesions."( Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Azam, F; Basso, M; Bonn, T; Chen, L; Clerin, V; Collini, M; Enroth, C; Farnegardh, M; Feingold, I; Goos-Nilsson, A; Halpern, A; Hu, B; Huselton, C; Keith, J; Liu, QY; Miller, C; Nambi, P; Quinet, E; Resmini, C; Savio, D; Singhaus, R; Unwalla, R; Wilhelmsson, A; Wrobel, J, 2006
)
0.33
"The use of a high quercetin dose to demonstrate its absorption and bioavailability does not reflect the real dietary situation because quercetin glycosides are usually present in small amounts in the human diet."( Phenylacetic acids were detected in the plasma and urine of rats administered with low-dose mulberry leaf extract.
Cheng, HM; Lee, CY; Sim, SM, 2008
)
1.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In the child, when the benzoate/phenylacetate dosage was increased from 200 to 375 mg/kg/day each, feeding decreased."( Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.
Batshaw, ML; Coyle, JT; Hyman, SL; Mellits, ED; Quaskey, S; Qureshi, IA; Robinson, MB, 1988
)
0.27
" One of six patients with glioblastoma multiforme, whose steroid dosage has remained unchanged for the duration of therapy, has sustained functional improvement for more than 9 months."( A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Cooper, MR; Figg, WD; Headlee, DJ; McCall, NA; Samid, D; Sartor, AO; Thibault, A; Tompkins, AC; Venzon, DJ; Weinberger, MS, 1994
)
0.29
" Ambiguous medical prescriptions and inadequate cross-checking of drug dosage by physicians, nurses and pharmacists were the main causes of these incidents."( Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia.
Boyadjiev, SA; Brusilow, SW; Geraghty, MT; Praphanphoj, V; Waber, LJ, 2000
)
0.31
" The prepared sodium phenylacetate powder was orally administered to a 16-year-old patient with CTLN2 at a dosage of 12 g/d."( Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy.
Hashimoto, G; Honda, S; Horiuchi, R; Kaneko, H; Konno, Y; Nagai, K; Oshima, Y; Sekizuka, M; Tomomasa, T; Yamamoto, K, 2002
)
0.31
"The capacity-limited conversion of PAA to PAG has important implications for the dosing of PAA, and the pharmacokinetic model described here may be useful for individualizing the infusion rate of the drug in future clinical trials."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
" The steady state plasma concentrations of PA and phenylacetylglutamine were comparatively the same between the two dosing schedules."( A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.
Berger, MS; Chang, SM; Clifford Schold, S; Gilbert, M; Ian Robins, H; Kuhn, JG; Mehta, MP; Pollack, I; Prados, MD; Spence, AM, 2003
)
0.32
" A pharmacokinetic study of sodium phenylacetate/sodium benzoate (NAPA/NABZ) was performed in two groups of normal healthy volunteers, following the dosing regimen used to treat hyperammonemia."( Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers.
Altincatal, A; MacArthur, RB; Tuchman, M, 2004
)
0.32
" Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA)."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
"We have analyzed pharmacokinetic data for glycerol phenylbutyrate (also GT4P or HPN-100) and sodium phenylbutyrate with respect to possible dosing biomarkers in patients with urea cycle disorders (UCD)."( Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Bart, S; Bartholomew, D; Bartley, J; Berquist, W; Berry, SA; Cederbaum, S; Coakley, DF; Diaz, GA; Dickinson, K; Dorrani, N; Feigenbaum, A; Gallagher, R; Harding, CO; Korson, MS; Kronn, D; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Mokhtarani, M; Moors, TL; Rhead, W; Scharschmidt, BF; Smith, W; Sreenath-Nagamani, S; Summar, M; Vockley, J; Zori, R, 2012
)
0.38
" The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.81
" Covariate analyses indicated that age did not influence the PK parameters, with body surface area (BSA) being the most significant covariate, reinforcing current BSA based dosing recommendations as seen in older patients."( Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry, SA; Diaz, GA; Dong, M; Ficicioglu, C; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Perdok, R; Robinson, B; Smith, WE; Vinks, AA; Vockley, J; Zori, R, 2018
)
0.48
" Ornithine phenylacetate, an intravenous dosage form of the L-ornithine salt of phenylacetate, is under development for hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.99
"This analysis summarized the pharmacokinetics and safety of ornithine phenylacetate to support the dosing strategy and to assist with the monitoring and management of neurologic adverse events in a global clinical development program."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.99
"With a flat dosing algorithm, special consideration must be given to patients with a small body size (i."( Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Vilchez, RA; Wang, X, 2022
)
0.94
" Plasma concentrations of their primary metabolite, phenylacetate (PAA), as well as the ratio of PAA to phenylacetylglutamine (PAGN) are useful for guiding dosing and detecting toxicity."( Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn.
Burrage, LC; Elsea, SH; Glinton, KE; Liu, N; Minard, CG; Nagamani, SCS; Sun, Q, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (10)

RoleDescription
auxinAny of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").
toxinPoisonous substance produced by a biological organism such as a microbe, animal or plant.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
EC 6.4.1.1 (pyruvate carboxylase) inhibitorAn EC 6.4.1.* (carboxylase) inhibitor that interferes with the action of pyruvate carboxylase (EC 6.4.1.1).
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
plant growth retardantnull
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
phenylacetic acidsAny monocarboxylic acid that is phenylacetic acid or its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Phenylacetate Metabolism38
Phenylethylamine Metabolism1226
Phenylalanine degradation ( Phenylalanine degradation )1314
NAD+ + Phenyl-acetaldehyde + H2O = NADH + Phenyl-acetic acid ( Phenylalanine degradation )45
Flavan-3-ol metabolic pathway070

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency47.87770.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.83250.001019.414170.9645AID743094
thyroid stimulating hormone receptorHomo sapiens (human)Potency33.49150.001628.015177.1139AID1259385
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency14.96010.000323.4451159.6830AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.57320.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)96.00000.00101.191310.0000AID309933
Aldo-keto reductase family 1 member B1Homo sapiens (human)Ki253.00000.01903.41939.3000AID1797503
Prolyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)Ki20,000.00005.00007.66679.0000AID1799825
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor class A-like protein 1Danio rerio (zebrafish)EC50 (µMol)30.50001.90001.90001.9000AID1802885
Tyrosine-protein kinase LckHomo sapiens (human)Kd50,000.00000.00021.117424.2210AID99714
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
procollagen-proline 4-dioxygenase activityProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
iron ion bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
L-ascorbic acid bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
endoplasmic reticulum lumenProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
endoplasmic reticulumProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay IDTitleYearJournalArticle
AID1797503Enzyme Inhibition Assay from Article 10.1016/j.bioorg.2006.09.004: \\Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.\\2006Bioorganic chemistry, Dec, Volume: 34, Issue:6
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.
AID1802885Functional Calcium Imaging Assay from Article 10.1074/jbc.M114.573162: \\ORA1, a zebrafish olfactory receptor ancestral to all mammalian V1R genes, recognizes 4-hydroxyphenylacetic acid, a putative reproductive pheromone.\\2014The Journal of biological chemistry, Jul-11, Volume: 289, Issue:28
ORA1, a zebrafish olfactory receptor ancestral to all mammalian V1R genes, recognizes 4-hydroxyphenylacetic acid, a putative reproductive pheromone.
AID1799825Inhibition Assay from Article : \\Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.\\1986The Journal of biological chemistry, Jun-15, Volume: 261, Issue:17
Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.
AID1569194Osteo-blastogenic activity in mouse MC3T3-E1 cells assessed as stimulation of ALP activity at 10 uM supplemented with fresh medium every 3 to 4 days and measured after 14 days relative to control
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1750491Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient at 100 uM pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis relative to control2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID309933Inhibition of aldose reductase2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
AID1232386Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 3 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1569195Osteo-blastogenic activity in mouse MC3T3-E1 cells assessed as stimulation of ALP activity at 50 uM supplemented with fresh medium every 3 to 4 days and measured after 14 days relative to control
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1865413Inhibition of full length recombinant C-terminal FLAG-tagged human HDAC2 expressed in baculovirus-infected Sf9 cells at 1 mM measured for 2 hrs by fluorescence-based assay relative to control2022ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10
Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1232383Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 3 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1232388Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 9 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1819261Binding affinity to Pseudomonas aeruginosa MurB assessed as change in melting temperature at 5 mM by differential scanning fluorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of Novel Inhibitors of Uridine Diphosphate-
AID360810Inhibition of tyrosin kinase pp60src1995Journal of natural products, Dec, Volume: 58, Issue:12
Chemical constituents of halophilic facultatively anaerobic bacteria, 1.
AID99714Binding affinity against Lck SH2 domain1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain.
AID1222956Cmax in rat hepatocytes treated with 100 uM MFA after 30 mins incubation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1232385Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 9 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID477925Antiplasmodial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3]H-hypoxanthine incorporation assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Jacaranone-derived glucosidic esters from Jacaranda glabra and their activity against Plasmodium falciparum.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID342465Activity at human recombinant PON1 assessed as hydrolysis of lactone ring at 1 mM by Ellman's method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity.
AID1819260Binding affinity to Pseudomonas aeruginosa MurB assessed as change in melting temperature at 1 mM by differential scanning fluorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of Novel Inhibitors of Uridine Diphosphate-
AID477926Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Jacaranone-derived glucosidic esters from Jacaranda glabra and their activity against Plasmodium falciparum.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1232384Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate at 6 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1232387Inhibition of diphenolase activity of mushroom tyrosinase using L-dopa as substrate at 6 mM by spectrophotometric assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Identification of p-hydroxybenzyl alcohol, tyrosol, phloretin and its derivate phloridzin as tyrosinase substrates.
AID1569185Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1750492Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (767)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990159 (20.73)18.7374
1990's167 (21.77)18.2507
2000's236 (30.77)29.6817
2010's160 (20.86)24.3611
2020's45 (5.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.44 (24.57)
Research Supply Index6.73 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index123.94 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (2.46%)5.53%
Reviews28 (3.44%)6.00%
Case Studies23 (2.83%)4.05%
Observational0 (0.00%)0.25%
Other742 (91.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes [NCT03712280]Phase 250 participants (Actual)Interventional2018-12-01Completed
An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects With Varying Degrees of Cirrhosis [NCT03846843]Phase 130 participants (Actual)Interventional2016-08-15Completed
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury [NCT01548690]Phase 247 participants (Actual)Interventional2012-06-30Completed
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study) [NCT01966419]Phase 2231 participants (Actual)Interventional2014-01-07Completed
Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure [NCT01634230]0 participants Expanded AccessNo longer available
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy [NCT00597909]Phase 21 participants (Actual)Interventional2007-12-31Terminated(stopped due to Study was terminated due to lack of enrollment and business decisions.)
Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding [NCT01434108]Phase 2/Phase 348 participants (Actual)Interventional2011-10-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia As [NCT04128462]Phase 30 participants (Actual)Interventional2021-11-30Withdrawn(stopped due to Business Decision)
Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors [NCT00003241]Phase 20 participants Interventional1998-05-31Completed
[NCT00004767]Phase 220 participants Interventional1985-01-31Completed
Human Metabolism of Ornithine Phenylacetate: A Study in Healthy Volunteers [NCT03159390]20 participants (Actual)Interventional2015-02-28Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01548690 (5) [back to overview]Change in Ammonia
NCT01548690 (5) [back to overview]Measurement of OCR-002 Plasma Concentration
NCT01548690 (5) [back to overview]Neurological Function Measured by the Orientation Log (O-log)
NCT01548690 (5) [back to overview]Neurological Function Measured by the West Haven Criteria (WHC) for Hepatic Encephalopathy
NCT01548690 (5) [back to overview]Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability
NCT01966419 (1) [back to overview]Percentage of Participants in Each HE Stage
NCT03712280 (2) [back to overview]Ammonia Plasma Levels at Baseline and Day 5
NCT03712280 (2) [back to overview]Number of Participants With Adverse Events by the End of the Trial

Change in Ammonia

To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours

InterventionPercent Change (Mean)
Maximum Dose Level 3.33 g/24h41.2
Maximum Dose Level 6.65 g/24h16.6
Maximum Dose Level 10 g/24h41.8
Maximum Dose Level 20g/24h38.4

[back to top]

Measurement of OCR-002 Plasma Concentration

To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion

Interventionmicrograms per millileter (Mean)
Maximum Dose Level 3.33 g/24h65.6
Maximum Dose Level 6.65 g/24h32.2
Maximum Dose Level 10 g/24h33.4
Maximum Dose Level 20g/24h104.9

[back to top]

Neurological Function Measured by the Orientation Log (O-log)

The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h23.8
Maximum Dose Level 6.65 g/24h24.0
Maximum Dose Level 10 g/24h24.0
Maximum Dose Level 20g/24h24.0

[back to top]

Neurological Function Measured by the West Haven Criteria (WHC) for Hepatic Encephalopathy

The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h2.4
Maximum Dose Level 6.65 g/24h3.2
Maximum Dose Level 10 g/24h1.6
Maximum Dose Level 20g/24h1.8

[back to top]

Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability

To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Maximum Dose Level 3.33 g/24h0
Maximum Dose Level 6.65 g/24h0
Maximum Dose Level 10 g/24h0
Maximum Dose Level 20g/24h0

[back to top]

Percentage of Participants in Each HE Stage

"To support the primary endpoint of confirmed clinical response, the investigator rated participants on a 4-point staging scale, where higher scores are worse.~The stages are described as:~Stage 0/1 = Participant has no tremor of the hand when the wrist is extended (asterixis) and no confusion, even about where they are (disorientation) Stage 2 = Participant has tremor of the hand when the wrist is extended (asterixis) and is confused, not knowing where they are (disorientation) Stage 3 = Participant is tired, falling asleep, answers questions but is confused, and doesn't know where they are (Stupor, arousable but falls asleep, responsive to verbal stimuli, Obvious confusion, Gross disorientation) Stage 4 = Participant is unconscious (in a coma)" (NCT01966419)
Timeframe: Baseline to End of Study (through 3 hours post end-of-infusion)

,
Interventionpercentage of participants (Number)
Baseline : Stage 4Baseline : Stage 3Baseline : Stage 2Baseline : Stage 0/1Baseline : MissingDay 1, 7 am : Stage 4Day 1, 7 am : Stage 3Day 1, 7 am : Stage 2Day 1, 7 am : Stage 0/1Day 1, 7 am : MissingDay 1, 5 pm : Stage 4Day 1, 5 pm : Stage 3Day 1, 5 pm : Stage 2Day 1, 5 pm : Stage 0/1Day 1, 5 pm : MissingDay 2, 7 am : Stage 4Day 2, 7 am : Stage 3Day 2, 7 am : Stage 2Day 2, 7 am : Stage 0/1Day 2, 7 am : MissingDay 2, 5 pm : Stage 4Day 2, 5 pm : Stage 3Day 2, 5 pm : Stage 2Day 2, 5 pm : Stage 0/1Day 2, 5 pm : MissingDay 3, 7 am : Stage 4Day 3, 7 am : Stage 3Day 3, 7 am : Stage 2Day 3, 7 am : Stage 0/1Day 3, 7 am : MissingDay 3, 5 pm : Stage 4Day 3, 5 pm : Stage 3Day 3, 5 pm : Stage 2Day 3, 5 pm : Stage 0/1Day 3, 5 pm : MissingDay 4, 7 am : Stage 4Day 4, 7 am : Stage 3Day 4, 7 am : Stage 2Day 4, 7 am : Stage 0/1Day 4, 7 am : MissingDay 4, 5 pm : Stage 4Day 4, 5 pm : Stage 3Day 4, 5 pm : Stage 2Day 4, 5 pm : Stage 0/1Day 4, 5 pm : MissingDay 5, 7 am : Stage 4Day 5, 7 am : Stage 3Day 5, 7 am : Stage 2Day 5, 7 am : Stage 0/1Day 5, 7 am : MissingDay 5, 5 pm : Stage 4Day 5, 5 pm : Stage 3Day 5, 5 pm : Stage 2Day 5, 5 pm : Stage 0/1Day 5, 5 pm : MissingDay 6, 7 am : Stage 4Day 6, 7 am : Stage 3Day 6, 7 am : Stage 2Day 6, 7 am : Stage 0/1Day 6, 7 am : MissingDay 6, 5 pm : Stage 4Day 6, 5 pm : Stage 3Day 6, 5 pm : Stage 2Day 6, 5 pm : Stage 0/1Day 6, 5 pm : MissingEnd of Study : Stage 4End of Study : Stage 3End of Study : Stage 2End of Study : Stage 0/1End of Study : Missing
Ornithine Phenylacetate640680204300514361041569100496116021055250394527009403000734280072832003222800324270037503728550
Placebo113071030020007320032161100314571603155021037462002542280254228009292300824230010212300356051031450

[back to top]

Ammonia Plasma Levels at Baseline and Day 5

"This test measures the level of ammonia in your blood. Ammonia, also known as NH3, is a waste product made by your body during the digestion of protein. Normally, ammonia is processed in the liver, where it is changed into another waste product called urea. Urea is passed from the body in urine.~If your body cannot process or eliminate ammonia, a lab test of a blood sample shows it has built up in the bloodstream. High ammonia levels in the blood can lead to serious health problems, including hepatic encephalopathy." (NCT03712280)
Timeframe: Baseline, Day 5

,,,
Interventionμmol/L (Mean)
BaselineDay 5/Pre-Dose in the MorningDay 5/4 Hours Post Morning Dose
Group A: MNK6106 2 Grams (Tid)70.472.769.8
Group B: MNK6106 4 Grams (Bid)91.463.960.9
Group C: MNK6106 4 Grams (Tid)92.674.973.0
Group D: Rifaximin 550 mg (Bid)78.175.871.6

[back to top]

Number of Participants With Adverse Events by the End of the Trial

End of trial is defined as 7 (+/-3) days after last study treatment (NCT03712280)
Timeframe: within 15 days

,,,
InterventionParticipants (Count of Participants)
Affected by Serious Adverse EventsAffected by Any Non-serious Adverse EventAffected by Non-serious Adverse Events in the 5% Reporting Threshold
Group A: MNK6106 2 Grams (Tid)055
Group B: MNK6106 4 Grams (Bid)066
Group C: MNK6106 4 Grams (Tid)298
Group D: Rifaximin 550 mg (Bid)055

[back to top]